NEWS
PRESS CENTER
[Announcements and Notices] - INSIDE INFORMATION POSITIVE TOPLINE RESULTS PHASE III CLINICAL TRIAL (AFFIRM-205) OF LAE002 (AFURESERTIB) MET PRIMARY ENDPOINT OF PFS DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFITS IN PATIENTS WITH PIK3CA/AKT1/PTEN ALTERATIONS AND HR+/HER2- LA/mBC
2026-04-15
Recommendation
-
2024-11-20Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of ObesityMore -
2024-06-26Laekna Announces First Subject Dosed in Phase I Clinical Trial of LAE102 (a monoclonal antibody against ActRIIA) in China for The Treatment of ObesityMore
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
Follow us on Linkedin
Copyright © Laekna Therapeutics, All Rights Reserved. Privacy Policy
